A Phase 3, Randomized, Open-Label, Active-Controlled, Multicenter, Non-Inferiority Study to Evaluate the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With Chronic Kidney Disease on Dialysis
Latest Information Update: 12 Jan 2025
At a glance
- Drugs Pegmolesatide (Primary) ; Epoetin alfa
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Sponsors Jiangsu Hansoh Pharmaceutical
Most Recent Events
- 06 May 2024 According to Jiangsu Hansoh Pharmaceutical media release, data from this study was published in The Lancet in October 2023.
- 07 Mar 2023 Status changed from recruiting to completed.
- 17 Sep 2021 Planned End Date changed from 31 Dec 2020 to 30 Sep 2021.